AZN Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 17.27
- PEG ratio
- 1.36
- P/B
- 5.83
- P/S (TTM)
- 4.49
- EV/EBITDA
- 15.23
Profitability & growth
- ROE (TTM)
- 23.5%
- Operating margin
- 27.9%
- Revenue growth YoY
- 12.5%
- Dividend yield
- 1.8%
- Beta
- 0.21
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About AstraZeneca PLC
Company profileAstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1 FRANCIS CRICK AVENUE, CAMBRIDGE, UNITED KINGDOM
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
